Helix BioPharma Corp.
HBPCF · OTC
10/31/2025 | 7/31/2025 | 4/30/2025 | 1/31/2025 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -19.59 | 0.17 | -0.09 | 0.00 |
| FCF Yield | -0.47% | -1.05% | -17.30% | -14.70% |
| EV / EBITDA | -184.60 | 93.41 | -4.72 | -3.22 |
| Quality | ||||
| ROIC | -3.96% | -6.45% | 111.73% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.86 | 0.68 | 0.89 | 0.68 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -86.11% | 66.08% | -46.60% | -9.41% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 0.41 | 0.46 | 1.46 |
| Interest Coverage | -85.73 | -321.00 | -1,553.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -130,140.25 | 0.00 | 0.00 | 0.00 |